Data Sheet (Cat.No.T23555)

TargetMol

Z-VEID-FMK

Chemical Properties



CAS No. : 210344-96-0

Formula: C31H45FN4O10

Molecular Weight: 652.71

Storage: Keep away from moisture,Store under nitrogen
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Z-VEID-FMK is a selective and cell-permeable caspase-6 peptide inhibitor that irreversibly covalently binds to the active site of the enzyme, thereby inhibiting apoptosis and DNA breakage.
Targets(IC50)	Apoptosis,Caspase
In vitro	Pretreatment of HepG2 by Z-VEID-FMK (50 μM, 1 h) reduced drug-induced caspase-6 activity in HepG2 cells by 53%, reduced apoptosis by 58%, and reduced DNA breakage by 44%. [1]

Solubility Information

Solubility	DMSO: 200 mg/mL (306.41 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 5 mg/mL (7.66 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5321 mL	7.6604 mL	15.3207 mL
5 mM	0.3064 mL	1.5321 mL	3.0641 mL
10 mM	0.1532 mL	0.766 mL	1.5321 mL
50 mM	0.0306 mL	0.1532 mL	0.3064 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

S-T Lee, et al. Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J Anaesth. 2009 Jan;102(1):80-9.
Su, Kuan-Wei, et al. Repurposing cabozantinib with therapeutic potential in KIT-driven t (8; 21) acute myeloid leukaemias.. Cancer Gene Therapy. 2022 May;29(5):519-532. doi: 10.1038/s41417-021-00329-1. Epub 2021 Apr 8.
Philippe P Monnier, et al. Involvement of caspase-6 and caspase-8 in neuronal apoptosis and the regenerative failure of injured retinal ganglion cells. J Neurosci. 2011 Jul 20;31(29):10494-505.